Esophageal Cancer - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 355
   

Global Markets Direct’s, ‘Esophageal Cancer Pipeline Review, H2 2015’, provides an overview of the Esophageal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Esophageal Cancer - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Esophageal Cancer - Overview 11
Pipeline Products for Esophageal Cancer - Comparative Analysis 12
Esophageal Cancer - Therapeutics under Development by Companies 13
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Esophageal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Esophageal Cancer - Products under Development by Companies 21
Esophageal Cancer - Products under Investigation by Universities/Institutes 25
Esophageal Cancer - Companies Involved in Therapeutics Development 26
Adaptimmune Limited 26
Advantagene, Inc. 27
Advaxis, Inc. 28
Amgen Inc. 29
ArQule, Inc. 30
Array BioPharma Inc. 31
Aslan Pharmaceuticals Pte. Ltd. 32
AstraZeneca Plc 33
ATLAB Pharma SAS 34
AVEO Pharmaceuticals, Inc. 35
Bayer AG 36
Boehringer Ingelheim GmbH 37
Celgene Corporation 38
Celldex Therapeutics, Inc. 39
Cellectar Biosciences, Inc. 40
Cerulean Pharma, Inc. 41
Cyclacel Pharmaceuticals, Inc. 42
Daiichi Sankyo Company, Limited 43
Genmab A/S 44
Glycotope GmbH 45
Hutchison MediPharma Limited 46
Ignyta, Inc. 47
ImmunoFrontier, Inc. 48
ImmunoGen, Inc. 49
Immunomedics, Inc. 50
Johnson & Johnson 51
Karyopharm Therapeutics, Inc. 52
MacroGenics, Inc. 53
Mebiopharm Co., Ltd. 54
MedImmune, LLC 55
Novartis AG 56
Omeros Corporation 57
Omnitura Therapeutics Inc. 58
Oncolys BioPharma Inc. 59
Ono Pharmaceutical Co., Ltd. 60
Pfizer Inc. 61
Precision Biologics, Inc. 62
Proteo, Inc. 63
Puma Biotechnology, Inc. 64
Shionogi & Co., Ltd. 65
Spectrum Pharmaceuticals, Inc. 66
Symphogen A/S 67
Synta Pharmaceuticals Corp. 68
Transgene Biotek Limited 69
VioQuest Pharmaceuticals, Inc. 70
Virocan Therapeutics Private Limited 71
Zhejiang BetaPharma Co., Ltd. 72
Esophageal Cancer - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Target 74
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
1-BB1 - Drug Profile 85
ADXS-HER2 - Drug Profile 87
afatinib dimaleate - Drug Profile 88
alpelisib - Drug Profile 92
AMG-337 - Drug Profile 94
ATL-101 - Drug Profile 95
binimetinib - Drug Profile 97
CDX-1401 - Drug Profile 102
Cell Therapy 1 for Oncology - Drug Profile 104
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 105
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 107
cetuximab biobetter - Drug Profile 108
CRLX-101 - Drug Profile 109
CYC-140 - Drug Profile 112
dacomitinib - Drug Profile 113
DKN-01 - Drug Profile 116
durvalumab - Drug Profile 118
elgemtumab - Drug Profile 121
ficlatuzumab - Drug Profile 123
futuximab - Drug Profile 125
ganetespib - Drug Profile 127
gedatolisib - Drug Profile 131
gefitinib - Drug Profile 133
Gene Therapy for Esophageal Cancer - Drug Profile 138
Gene Therapy to Activate p53 for Oncology - Drug Profile 139
HMPL-309 - Drug Profile 140
HuMax-TF-ADC - Drug Profile 141
I131-CLR1404 - Drug Profile 143
icotinib hydrochloride - Drug Profile 145
IMF-001 - Drug Profile 147
IMGN-289 - Drug Profile 148
JNJ-42756493 - Drug Profile 149
margetuximab - Drug Profile 151
MBP-426 - Drug Profile 153
MMD-37K - Drug Profile 155
MVXONCO-1 - Drug Profile 156
NEO-201 - Drug Profile 157
neratinib - Drug Profile 158
nimotuzumab - Drug Profile 163
nintedanib - Drug Profile 167
nivolumab - Drug Profile 172
OBP-301 - Drug Profile 179
OMN-54 - Drug Profile 180
paclitaxel albumin bound - Drug Profile 182
panitumumab - Drug Profile 186
pasireotide LAR - Drug Profile 189
patritumab - Drug Profile 191
PCA-062 - Drug Profile 193
pralatrexate - Drug Profile 194
PTVICN-001 - Drug Profile 197
rAAV-VICN003 - Drug Profile 198
RXDX-106 - Drug Profile 199
S-588410 - Drug Profile 201
sacituzumab govitecan - Drug Profile 202
selinexor - Drug Profile 204
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 210
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 211
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 212
SMYD-2BAY02 - Drug Profile 213
TBL-0805E - Drug Profile 214
tiprelestat - Drug Profile 215
tivantinib - Drug Profile 218
triciribine phosphate - Drug Profile 220
Vaccine for Esophageal Cancer - Drug Profile 223
Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile 224
varlitinib - Drug Profile 225
Esophageal Cancer - Recent Pipeline Updates 228
Esophageal Cancer - Dormant Projects 336
Esophageal Cancer - Discontinued Products 340
Esophageal Cancer - Product Development Milestones 341
Featured News & Press Releases 341
Appendix 349
Methodology 349
Coverage 349
Secondary Research 349
Primary Research 349
Expert Panel Validation 349
Contact Us 349
Disclaimer 350

List of Tables

Number of Products under Development for Esophageal Cancer, H2 2015 16
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd..1) 20
Number of Products under Development by Companies, H2 2015 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Late Stage Development, H2 2015 23
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd..1) 27
Products under Development by Companies, H2 2015 (Contd..2) 28
Products under Development by Companies, H2 2015 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2015 30
Esophageal Cancer - Pipeline by Adaptimmune Limited, H2 2015 31
Esophageal Cancer - Pipeline by Advantagene, Inc., H2 2015 32
Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2015 33
Esophageal Cancer - Pipeline by Amgen Inc., H2 2015 34
Esophageal Cancer - Pipeline by ArQule, Inc., H2 2015 35
Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2015 36
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015 37
Esophageal Cancer - Pipeline by AstraZeneca Plc, H2 2015 38
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 39
Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 40
Esophageal Cancer - Pipeline by Bayer AG, H2 2015 41
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 42
Esophageal Cancer - Pipeline by Celgene Corporation, H2 2015 43
Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 44
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015 45
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 46
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 47
Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 48
Esophageal Cancer - Pipeline by Genmab A/S, H2 2015 49
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2015 50
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 51
Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2015 52
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015 53
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H2 2015 54
Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2015 55
Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2015 56
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 57
Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2015 58
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015 59
Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2015 60
Esophageal Cancer - Pipeline by Novartis AG, H2 2015 61
Esophageal Cancer - Pipeline by Omeros Corporation, H2 2015 62
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015 63
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015 64
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 65
Esophageal Cancer - Pipeline by Pfizer Inc., H2 2015 66
Esophageal Cancer - Pipeline by Precision Biologics, Inc., H2 2015 67
Esophageal Cancer - Pipeline by Proteo, Inc., H2 2015 68
Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015 69
Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015 70
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 71
Esophageal Cancer - Pipeline by Symphogen A/S, H2 2015 72
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 73
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2015 74
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015 75
Esophageal Cancer - Pipeline by Virocan Therapeutics Private Limited, H2 2015 76
Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015 77
Assessment by Monotherapy Products, H2 2015 78
Number of Products by Stage and Target, H2 2015 80
Number of Products by Stage and Mechanism of Action, H2 2015 84
Number of Products by Stage and Route of Administration, H2 2015 87
Number of Products by Stage and Molecule Type, H2 2015 89
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H2 2015 233
Esophageal Cancer - Dormant Projects, H2 2015 341
Esophageal Cancer - Dormant Projects (Contd..1), H2 2015 342
Esophageal Cancer - Dormant Projects (Contd..2), H2 2015 343
Esophageal Cancer - Dormant Projects (Contd..3), H2 2015 344
Esophageal Cancer - Discontinued Products, H2 2015 345

List of Figures

Number of Products under Development for Esophageal Cancer, H2 2015 16
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 18
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Products, H2 2015 25
Assessment by Monotherapy Products, H2 2015 78
Number of Products by Top 10 Targets, H2 2015 79
Number of Products by Stage and Top 10 Targets, H2 2015 79
Number of Products by Top 10 Mechanism of Actions, H2 2015 83
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 83
Number of Products by Top 10 Routes of Administration, H2 2015 86
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 86
Number of Products by Top 10 Molecule Types, H2 2015 88
Number of Products by Stage and Top 10 Molecule Types, H2 2015 88

Published By: Global Markets Direct
Product Code: Global Markets Direct13308


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: